Monophosphoryl lipid A directly regulates Th1 cytokine production in human CD4+ T-cells through Toll-like Receptor 2 and 4

Immunobiology ◽  
2021 ◽  
pp. 152132
Author(s):  
Mousa Komai-Koma ◽  
Yuan Ji ◽  
Hui Cao ◽  
Zhigang Liu ◽  
Charles McSharry ◽  
...  
Keyword(s):  
T Cells ◽  
Cd4 T Cells ◽  
Lipid A ◽  
Cytokine Production ◽  
Toll Like Receptor ◽  
Monophosphoryl Lipid A ◽  
Monophosphoryl Lipid ◽  
Th1 Cytokine ◽  
Toll Like Receptor 2

scholarly journals Dexamethasone and Monophosphoryl Lipid A-Modulated Dendritic Cells Promote Antigen-Specific Tolerogenic Properties on Naive and Memory CD4+ T Cells

2016 ◽  
Vol 7 ◽  
Author(s):  
Jaxaira Maggi ◽  
Katina Schinnerling ◽  
Bárbara Pesce ◽  
Catharien M. Hilkens ◽  
Diego Catalán ◽  
...  
Keyword(s):  
T Cells ◽  
Dendritic Cells ◽  
Cd4 T Cells ◽  
Lipid A ◽  
Monophosphoryl Lipid A ◽  
Monophosphoryl Lipid ◽  
Memory Cd4 T Cells

scholarly journals The Toll-Like Receptor 4 Agonist Monophosphoryl Lipid A Augments Innate Host Resistance to Systemic Bacterial Infection

2011 ◽  
Vol 79 (9) ◽  
pp. 3576-3587 ◽  
Author(s):  
Christopher D. Romero ◽  
Tushar K. Varma ◽  
Jason B. Hobbs ◽  
Aimee Reyes ◽  
Brandon Driver ◽  
...  
Keyword(s):  
Lipid A ◽  
Cytokine Production ◽  
Myeloid Cells ◽  
Innate Immune ◽  
Bacterial Clearance ◽  
Toll Like Receptor ◽  
Toll Like Receptor 4 ◽  
Monophosphoryl Lipid A ◽  
Monophosphoryl Lipid ◽  
Systemic Dissemination

ABSTRACTMonophosphoryl lipid A (MPLA) is a Toll-like receptor 4 (TLR4) agonist that is currently used as a vaccine adjuvant in humans. In this study, we evaluated the effect of MPLA treatment on the innate immune response to systemic bacterial infections in mice. Mice treated with MPLA after burn injury showed improved survival and less local and systemic dissemination of bacteria in a model ofPseudomonas aeruginosaburn wound infection. Prophylactic treatment with MPLA significantly enhanced bacterial clearance at the site of infection and reduced systemic dissemination of bacteria despite causing attenuation of proinflammatory cytokine production during acute intra-abdominal infection caused by cecal ligation and puncture. Administration of MPLA at 1 h after CLP also improved bacterial clearance but did not alter cytokine production. MPLA treatment increased the numbers of granulocytes, double-positive myeloid cells, and macrophages at sites of infection and increased the percentage and total numbers of myeloid cells mediating phagocytosis of bacteria. Depletion of Ly6G+neutrophils, but not macrophages, eliminated the ability of MPLA treatment to improve bacterial clearance. The immunomodulatory effects of MPLA were absent in TLR4-deficient mice. In conclusion, these studies show that MPLA treatment significantly augments the innate immune response to bacterial infection by enhancing bacterial clearance despite the attenuation of proinflammatory cytokine production. The enhanced bacterial clearance is mediated, in part, by increased numbers of myeloid cells with effective phagocytic functions at sites of infection and is TLR4 dependent.

The Protective Role of Toll-Like Receptor Agonist Monophosphoryl Lipid A Against Vaccinated Murine Schistosomiasis

2020 ◽  
Vol 65 (3) ◽  
pp. 652-660
Author(s):  
Ibrahim Aly ◽  
Essam H. Ibrahim ◽  
Rabab S. Hamad ◽  
Hoda E. L. Sayed ◽  
Sama M. N. Attiyah ◽  
...  
Keyword(s):  
Receptor Agonist ◽  
Lipid A ◽  
Protective Role ◽  
Toll Like Receptor ◽  
Monophosphoryl Lipid A ◽  
Monophosphoryl Lipid

scholarly journals Promotion of Cellular and Humoral Immunity against Foot-and-Mouth Disease Virus by Immunization with Virus-Like Particles Encapsulated in Monophosphoryl Lipid A and Liposomes

Vaccines ◽  
2020 ◽  
Vol 8 (4) ◽  
pp. 633
Author(s):  
Woo Sik Kim ◽  
Yong Zhi ◽  
Huichen Guo ◽  
Eui-Baek Byun ◽  
Jae Hyang Lim ◽  
...  
Keyword(s):  
T Cells ◽  
Immune Responses ◽  
Lipid A ◽  
Foot And Mouth Disease ◽  
Mouth Disease ◽  
Virus Like Particles ◽  
Monophosphoryl Lipid A ◽  
Monophosphoryl Lipid ◽  
Foot And Mouth ◽  
Ifn Γ

Virus-like particles (VLPs) have emerged as promising vaccine candidates against foot-and-mouth disease (FMD). However, such vaccines provide a relatively low level of protection against FMD virus (FMDV) because of their poor immunogenicity. Therefore, it is necessary to design effective vaccine strategies that induce more potent immunogenicity. In order to investigate the means to improve FMD VLP vaccine (VLPFMDV) immunogenicity, we encapsulated VLPs (MPL/DDA-VLPFMDV) with cationic liposomes based on dimethyldioctadecylammonium bromide (DDA) and/or monophosphoryl lipid A (MPL, TLR4 agonist) as adjuvants. Unlike inactivated whole-cell vaccines, VLPFMDV were successfully encapsulated in this MPL/DDA system. We found that MPL/DDA-VLPFMDV could induce strong cell-mediated immune responses by inducing not only VLP-specific IFN-γ+CD4+ (Th1), IL-17A+CD4+ (Th17), and IFN-γ+CD8+ (activated CD8 response) T cells, but also the development of VLP-specific multifunctional CD4+ and CD8+ memory T cells co-expressing IFN-γ, TNF-α, and IL-2. In addition, the MPL/DDA-VLPFMDV vaccine markedly induced VLP-specific antibody titers; in particular, the vaccine induced greater Th1-predominant IgG responses than VLPFMDV only and DDA-VLPFMDV. These results are expected to provide important clues for the development of an effective VLPFMDV that can induce cellular and humoral immune responses, and address the limitations seen in current VLP vaccines for various diseases.

Sign in / Sign up

Export Citation Format

Share Document